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LETTERS TO THE EDITORRe: An Approach to Predicting
HSCT Outcome Using
HLA-Mismatch Information
Mapped on Protein Structure
Data
We wish to comment on 3 aspects of the recently
published article by Dudkiewicz et al [1]: (1) Table 1,
which erroneously summarizes current practice in
donor selection; (2) our concerns about the analyses at-
tempting to validate the recommendations in Table 1;
and (3) the use of contact energy calculations to predict
immunogenicity of specific HLA mismatches.
First, the guidelines listed in Table 1 are not
supported by the referenced 3 articles [2-4] published
by the National Marrow Donor Program (NMDP)
andCenter for International Blood andMarrowTrans-
plant Research (CIBMTR). Furthermore, the authors
did not cite an update to the NMDP matching guide-
lines published by Bray et al. [5] (free full text available
online), which incorporates themore recent findings by
Lee et al. in 2007 [4].Table 1. Corrections to the donor selection guidelines listed in the
Statements from Dudkiewicz et al [1]
Search for 10/10 match at 5 loci (HLA-A, B, C, DR, and DQ) B
Allele mismatch is less harmful than antigen mismatch T
Chose a donor with a mismatch in HLA-A over a mismatch in HLA-B In
Chose a mismatch with a lower number of amino acid
substitutions between alleles
N
If there are 2 1-mismatch donors with single amino acid substitution in the
same locus, choose the donor with the substitution outside the binding
groove
N
Because graft-versus-host disease (GVHD) may increase the risk of
hematopoietic stem cell transplant (HSCT)-related mortality, avoid
mismatches that could lead to GVHD
TSecond, the authors’ misrepresentation of the do-
nor matching recommendations confounds their vali-
dation assessment because they are not testing
current best practices. Dudkiewicz et al. also were
not able to adjust for the numerous other clinical vari-
ables known to influence transplant outcome beyond
HLA matching (disease, disease stage, patient age, cy-
tomegalovirus [CMV] status, etc.). Our corrections to
the guidelines listed in Table 1.
Finally, we look forward to learning more about the
contact energy calculations used to predict immunoge-
nicity of specific HLA mismatches. However, based on
the methods and data presented in this article, we ques-
tion the authors’ conclusions. The authors chose to
highlight 2 particular mismatches, HLAB*3501-
HLAB*3503 and HLAB*2702-HLAB*2705, because
they were the 2 most numerous groups in the database.
However, Figure 9, showing the survival curves for these
2 groups, is based on a total of 18 patients (4%of allmis-
matches in the database), and not adjusted for any clini-
cal characteristics. Conclusions based on such a small
number of cases are questionable because small popula-
tion imbalances can have dramatic effects.
We appreciate the opportunity to comment on the
manuscript, and caution readers to refer to the most
recent donor selection recommendations [5].article by Dudkiewicz et al [1].
Results in cited NMDP publications
oth the Flomenberg et al. [2]and Lee et al. [4] studies show that 8/8 matching
(HLA-A, B, C, and DRB1) was the minimum level of matching associated
with highest survival; DQ mismatches did not have a significant impact on
outcome.
he Flomenberg et al. [2] study suggested that allele mismatches had less of an
impact on outcome; however, the later and larger NMDP study by Lee and
colleagues[4] showed that both types of mismatches had an indistinguishable
impact on outcome. This was discussed in the updated guidelines published
by Bray et al. [5].
the Lee [4] study, single mismatches at HLA-A appeared to be more poorly
tolerated than at HLA-B and HLA-C, but the limited number of transplants
with isolated mismatches at HLA-B or HLA-C suggested that more research
was needed.
one of the NMDP publications cited addressed the impact of the number of
amino acid substitutions on outcome; however, the results of the Lee et al.
study [4] related to antigen versus allele differences suggest that the number
of amino acids that differ do not have an impact on outcome. In fact, other
published studies, some supported by the NMDP, did not find any evidence
for selecting an allele with a lower number of amino acid substitutions [6,7]
one of the NMDP publications cited addressed the impact of amino acid
differences outside of the antigen binding site. A study by Xiao et al. [8]
(published after Dudkiewicz et al. [1] submitted their study) indicated that it
would not be possible to analyze the impact of these differences with the
current number of transplants.
he NMDP guidelines for matching published by Bray et al. [5] state that the
impact of HLA matching on survival should be of primary importance. The
effect of mismatching on GVHD, treatment-related mortality (TRM), and
rejection should be considered in the development of a risk-adapted
treatment strategy.
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doi:10.1016/j.bbmt.2010.02.012Cyclosporine Dose Intensity
and Risk of Acute Graft-
versus-Host Disease: Trough
versus Area under the Curve
Malard et al. [1] reported their observation of an
inverse correlation between cyclosporine (CsA) con-
centrations within the first 2 weeks after hematopoietic
stem cell transplantation (HSCT) and the severity of
acute graft-versus-host disease (aGVHD). CsA was
given first as a continuous i.v. infusion and then orally
in patients able to receive oral medication. CsA con-
centrations are referred to as ‘‘trough’’ concentrations,
with no distinction made with respect to route of ad-
ministration (continuous i.v. infusion vs oral). The
proportions of patients receiving i.v. and oral doses
each week after HSCT are not stated.
When doses are given on an intermittent schedule,
trough drug concentrations are obtained at the end of
a dosing interval and before administration of the next
dose. In contrast, drug concentrations can be deter-
mined at any time during a continuous infusion.
They can be either steady-state or non–steady-state
concentrations, depending on how long the infusion
rate is maintained. Ideally, steady-state concentra-
tions, whether drawn at the end of a dosing interval
or during a continuous i.v. infusion, are used to de-
scribe the relationship between a drug concentration
and a clinical endpoint. In any case, drug concentra-
tions obtained during continuous i.v. infusion do not
meet the definition of a trough concentration.
In centers where CsA is given by intermittent i.v. in-
fusion, trough whole blood concentrations are used to
individualize doses. Similar to the findings of Malard
et al., we reported that in 87 children undergoing mye-
loablative HSCT, higher trough CsA concentrations
during the week before engraftment significantly re-
duced theoddsofdeveloping severe aGVHD(univariate
analysis, P 5 .0409; multivariate analysis adjusted for
type of HSCT, P5 .0454) [2]. The majority of the chil-
dren (84 of 87) received a bone marrow transplant, and
the median day of engraftment was day 118 (mean,
day 119.2; range, day 111 to day 135). Therefore,
for many children, the week before engraftment coin-
cided with the second week posttransplantation.
Malard et al. [1] raised the question of whether area
under the curve (AUC) rather than troughconcentration
might be a more effective parameter on which to base
CsA dosing. Concentrations determined at steady state
in patients receiving continuous CsA i.v. infusion can
be used to estimate theAUC.Determination ofAUCaf-
ter intermittent i.v. infusion traditionally requiresmulti-
ple concentration-time points obtained during the
dosing interval. We have developed a limited sampling
strategy for determining CsA AUC after a 2-hour CsA
